Core Viewpoint - PharmaCorp RX Inc. has restated and refiled its financial statements for the interim period ended June 30, 2025, following a review by its Auditor, with certain accounting adjustments made that do not affect the overall financial position of the Corporation [1]. Financial Adjustments - The Amended Q2 2025 Statements show significant changes, including an increase in intangible assets from $4,847,651 to $6,937,651 and the addition of an acquired charter valued at $2,090,000 [2]. - The purchases of property and equipment were adjusted from $2,145,438 to $55,438, indicating a significant revision in asset reporting [2]. - The total assets and net cash used in investing activities remained unchanged despite these adjustments, indicating minimal impact on the overall financial health [3]. Notes and Revisions - Changes were made to the notes of the Amended Q2 2025 Statements, including a working capital adjustment for the acquisition of Atlantic Canada 1 amounting to $1,019,014 and the addition of the acquired charter as a line item [5]. - A footnote was added to clarify ownership restrictions under Ontario's Drug and Pharmacies Regulation Act, and amortization amounts were revised accordingly [5]. - Subsequent event notes were added to reflect the closing of the purchase of two pharmacies in Western Canada and one in Eastern Canada, as announced on October 2, 2025 [5]. Company Operations - PharmaCorp operates seven PharmaChoice Canada bannered pharmacies and plans to continue acquiring more pharmacies under this brand, as part of its strategic alliance with PharmaChoice Canada [4]. - The Corporation is also open to acquiring independently owned pharmacies and transitioning them to the PharmaChoice Canada banner [4]. - PharmaCorp actively seeks discussions with pharmacy owners regarding succession or sale, emphasizing a commitment to seamless transitions that protect legacies and serve communities [6].

Core Insights - Retail pharmacies and prescription drug savings site GoodRx are in discussions with the Trump administration regarding potential collaboration with the TrumpRx website, indicating a possible expansion of services beyond initial offerings [1] Group 1 - GoodRx is exploring opportunities to join the TrumpRx initiative, which may enhance its visibility and service offerings in the prescription drug market [1] - The discussions suggest a strategic move to align with government efforts to improve access to affordable medications [1]

Pharmacy giant Write has announced it's officially closed all of its stores. The company made the announcement on its website on Friday. Write aid filed for Chapter 11 bankruptcy back in May.Now, the company has promised a smooth transfer for customers with prescriptions there. So, if you're one of them, you can go to the Write Aid website to request your records and find a new. ...

Core Points - Rite Aid has officially closed all its stores following its Chapter 11 bankruptcy filing, marking its second bankruptcy since October 2023 [1][7] - The company faced significant financial challenges exacerbated by changes in the retail and healthcare sectors, with a reported loss of $750 million in the previous fiscal year [2][7] - Rite Aid's website now only provides a service for former customers to find new pharmacies and request pharmacy records [3] Bankruptcy and Store Closures - Rite Aid filed for Chapter 11 bankruptcy in May 2023 and announced the closure of all its stores as part of its bankruptcy plan [1][4] - At its peak, Rite Aid operated thousands of stores, but by May 2023, it had reduced to 1,240 locations across 15 states [6] Transition of Services - The company entered into agreements to transition its pharmacy services and assets to other pharmacy chains, including CVS Pharmacy and Walgreens, ensuring a smooth transfer of customer prescriptions [4] - CEO Matt Schroeder emphasized the importance of maintaining uninterrupted pharmacy services for customers and preserving jobs for associates during the transition [2][4] Asset Sales - Rite Aid auctioned its in-house ice cream brand, Thirty Ice Cream, to Hilrod Holdings for $19.2 million, with the transaction approved by a federal judge [5] - The company had previously owned Thrifty PayLess, Inc., which was part of the assets sold during the bankruptcy process [5] Debt Situation - After emerging from bankruptcy in 2024, Rite Aid was reported to still have $2.5 billion in debt [8]

Core Insights - PharmaCorp RX Inc. has completed the acquisition of three community pharmacy businesses, enhancing its presence in both Western and Eastern Canada [1][4] Western Canada Acquisitions - The company acquired two PharmaChoice Canada bannered pharmacies in Western Canada for an aggregate purchase price of $3,400,000, with 75% paid in cash and 25% through the issuance of common shares [2] - The common shares were priced based on the volume weighted average trading price on the TSX Venture Exchange over a specified period prior to the closing date [2] Eastern Canada Acquisition - PharmaCorp also acquired a PharmaChoice Canada bannered pharmacy in Eastern Canada for $5,300,000, funded through cash on hand and available credit [3] - No finder's fees were incurred in connection with these acquisitions [3] Strategic Growth - The acquisitions are part of PharmaCorp's disciplined growth strategy and strengthen its strategic alliance with PharmaChoice Canada [4] - The company aims to expand its national footprint while preserving independent legacies and ensuring continuity of care for patients [4] - PharmaCorp plans to remain active in pursuing further acquisitions in the near future [4] Company Overview - PharmaCorp currently operates seven PharmaChoice Canada bannered pharmacies and intends to continue acquiring both PharmaChoice and independently owned pharmacies [5] - The company is open to discussions with pharmacy owners considering succession or sale, emphasizing a commitment to seamless transitions [6]

Core Viewpoint - PharmaCorp RX Inc. has filed a preliminary short form base shelf prospectus to qualify the distribution of up to $100 million in various securities over a 25-month period, enhancing its ability to access capital markets for growth and acquisitions [2][3]. Company Overview - PharmaCorp is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners [5]. - The company operates four pharmacies under the PharmaChoice Canada banner and aims to acquire more pharmacies, rebranding them under its platform [5]. Financial Strategy - The base shelf prospectus will allow PharmaCorp to issue common shares, preferred shares, warrants, debt securities, subscription receipts, units, or any combination thereof, based on financial requirements and market conditions [2]. - The specific terms of any offerings will be detailed in prospectus supplements filed with Canadian securities regulatory authorities [2]. Corporate Development - The filing of the base shelf prospectus is seen as a milestone in PharmaCorp's corporate development, providing flexibility to access capital markets as acquisition opportunities arise [3]. - The strategic alliance with PharmaChoice Canada is highlighted as a key factor in advancing the company's national growth and operations platform [3].

Core Points - Bankruptcy is a legal process that provides relief from overwhelming debts but comes with specific limitations and obligations that must be adhered to [6][10][11] Group 1: Bankruptcy Process and Obligations - After filing for bankruptcy, individuals must complete a debtor education course to receive a discharge, and failure to comply with court orders can lead to case dismissal [1][2] - Both Chapter 7 and Chapter 13 bankruptcies require court oversight, including attending meetings and submitting documents [2][3] - There are waiting periods before individuals can file for bankruptcy again, with Chapter 7 requiring an 8-year wait and Chapter 13 a 4-year wait after a previous discharge [3][4] Group 2: Limitations Post-Bankruptcy - A bankruptcy filing significantly impacts credit reports, with Chapter 7 remaining for up to 10 years and Chapter 13 for up to 7 years, making it difficult to obtain new credit [6][7] - Certain debts, such as student loans, child support, and recent tax debts, are not dischargeable through bankruptcy [10] - Individuals cannot cosign loans immediately after bankruptcy due to being viewed as higher-risk borrowers [12][13] Group 3: Rebuilding and Financial Management - Rebuilding credit is essential after bankruptcy, and individuals are encouraged to adopt careful financial habits, including budgeting and using secured credit cards [14][15] - Honesty in future credit applications is crucial, as lying about past bankruptcy can lead to fraud charges [16][17] Group 4: Broader Implications - Bankruptcy can affect employment opportunities, particularly in finance-related jobs, and may complicate renting and insurance processes [20]

Core Points - The Swarthmore Avenue CVS Pharmacy has reopened, marking it as the first community pharmacy in the neighborhood, which enhances access to health and wellness essentials [1] Company Summary - CVS Health® has celebrated the reopening of the Pacific Palisades CVS Pharmacy store, indicating a commitment to improving community health access [1]

Core Viewpoint - PharmaCorp RX Inc. has entered into definitive share purchase agreements to acquire a 100% interest in two PharmaChoice Canada pharmacies in Western Canada for an aggregate purchase price of $3,400,000 [1][2]. Acquisition Details - The purchase price will be satisfied with 75% cash and 25% through the issuance of common shares, with the share price based on the volume weighted average trading price over a specified period [2]. - The acquisitions are expected to close around October 1, 2025, pending customary closing conditions [3]. Strategic Implications - The transactions demonstrate PharmaCorp's capability to execute accretive acquisitions, aligning with its strategic alliance with PharmaChoice Canada [4]. - PharmaCorp currently operates four PharmaChoice Canada pharmacies and plans to continue acquiring more pharmacies under this brand [4].

Financial Performance - Normalised revenue increased by 82.3% to $6.0085 billion[12, 21], and normalised EBIT increased by 41.4% to $834.5 million[11, 12, 21, 74] - Statutory NPAT increased by 40% to $579.1 million[12] - Pro-forma revenue reached $9.6 billion[13, 27], and pro-forma EBIT was $903.4 million[13, 27] - Net debt to normalised EBITDA ratio is 0.85x[14, 18, 37] Growth and Expansion - Chemist Warehouse (CW) retail network sales increased by 14% to $10.3 billion[10] - Australian CW franchise stores experienced 11.3% like-for-like sales growth[10, 30] - The company has expanded to 674 Chemist Warehouse stores globally[10, 46, 74] Synergies and Efficiencies - Synergies target upgraded to $100 million per annum by year four[10, 56, 58] - Distribution Centre (DC) volumes increased by 29% to over 532 million units[10, 57] - Logistics costs decreased by 11% per unit[10] Product Strategy - Over 20% growth in FY25 sales of own and exclusive label products[10, 54] - Launched Wagner generic medicines in November 2024[10, 54]